Portal de Periódicos da CAPES

High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses

2014; International Union Against Tuberculosis and Lung Disease; Volume: 18; Issue: 10 Linguagem: Inglês

10.5588/ijtld.13.0075

1815-8439

Alberto Piubello, Souleymane Hassane Harouna, Mahamadou Bassirou Souleymane, Ibrahim Boukary, Soumaila Morou, Moussa Toudou Daouda, Yahayé Hanki, Armand Van Deun,

Pneumocystis jirovecii pneumonia detection and treatment

Niger National Tuberculosis Programme. Regions supported by the Damien Foundation.To evaluate the effectiveness of a short-course standardised treatment regimen for patients with proven multidrug-resistant tuberculosis (MDR-TB) previously untreated with second-line drugs.Prospective study including all patients enrolled from 2008 to 2010. The 12-month standardised regimen comprised high doses of gatifloxacin, clofazimine, ethambutol and pyrazinamide throughout, supplemented by kanamycin, prothionamide and medium-high doses of isoniazid during the intensive phase of a minimum of 4 months. Patients were monitored using sputum smear and culture at start of treatment and every 2 months. Cured patients were followed up 6-monthly for 24 months.Sixty-five patients with MDR-TB were included and analysed. One of 58 patients tested for human immunodeficiency virus (1.7%) infection was positive. Twenty-five patients (39.7%) were severely affected (body mass index ⩿16 kg/m(2)). Cure was achieved in 58 patients (89.2%, 95%CI 81.7-96.7), 6 died and 1 defaulted. All 49 patients assessed at the 24-month follow-up after cure remained smear- and culture-negative. The main adverse events were vomiting (26.2%) and hearing impairment (20%), but no treatment had to be stopped.Standardised 12-month treatment for MDR-TB was highly effective and well tolerated in patients not previously exposed to second-line drugs in Niger.